Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
rifampicin · 1 trial · 1 indication
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
| Arm | Type | Description |
|---|---|---|
| Part 1 | EXPERIMENTAL | ecopipam 89.6 mg on Days 1 and 9 with repeat doses of itraconazole Days 6-16. |
| Part 2 | EXPERIMENTAL | ecopipam 179.2 mg on Days 1 and 13 with repeat doses of rifampicin days 6-20. |
| Name | Type | Description |
|---|---|---|
| Itraconazole | DRUG | itraconazole 200 mg QD Days 6 to 16 |
| rifampicin | DRUG | rifampicin 600 mg QD Days 6 to 20 |
| Ecopipam | DRUG | 89.6 mg on Days 1 and 9 for Part 1 or 179.2 mg on Days 1 and 13 for Part 2 |
Inclusion Criteria: * Male subjects or femail subjects of non-childbearing potential * ≥18 and ≤55 years of age * BMI \>18.5 and \<30.0 kg/m2 and body weight ≥50.0 kg for males and ≥45.0 kg for females. * Subjects must be healthy, as determined by the Investigator, based on medical history, physica...
Rifampicin is being studied for its role in drug interactions. It is an investigational small molecule being developed by Cognition Therapeutics, Inc. The drug is currently in Phase 1 clinical development, with one completed trial focused on drug interaction in healthy volunteers.
Rifampicin is a small molecule being studied for drug interactions. The specific molecular target of rifampicin has not been disclosed in the available information. It is being investigated for its effects on drug metabolism and interactions in healthy volunteers.
Rifampicin is being developed by Cognition Therapeutics, Inc., a biopharmaceutical company. The company is publicly traded under the ticker symbol CGTX. Cognition Therapeutics is conducting clinical research on rifampicin for drug interaction studies.
Rifampicin is in Phase 1 clinical development. It has completed one Phase 1 trial focused on drug interactions. The drug is investigational and has not been approved by regulatory authorities. It is being studied in healthy volunteers to assess drug interactions.
Rifampicin has one completed clinical trial registered under NCT06194864. This Phase 1 study was a drug interaction study conducted in Canada with 45 healthy volunteers aged 18 years and older. The trial was controlled but not randomized or double-blinded, and it included biomarker selection.
Rifampicin is also known by other names, though specific alternative names have not been provided. It is being developed by Cognition Therapeutics, Inc. under the name rifampicin. Readers searching for this drug should be aware that it may be referred to by different names in various contexts.